Juan Qin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Juan Qin has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
Duo Wang
2 shared publications- Gao-Jun Teng
Center of Interventional Radiology & Vascular Surgery, Department of Radiology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, China
2 shared publications - Hai-Dong Zhu
Center of Interventional Radiology and Vascular Surgery, Department of Radiology, Zhongda Hospital, Medical School, Southeast University, Nanjing 210009, China
2 shared publications Lin-Zhu Zhang
2 shared publicationsRui-Jie Du
Center of Interventional Radiology & Vascular Surgery, Department of Radiology, Nurturing Center of Jiangsu Province for State Laboratory of AI Imaging & Interventional Radiology (Southeast University), Basic Medicine Research and Innovation Center of Ministry of Education, Zhongda Hospital, Medical School, Southeast University, Nanjing, People's Republic of China
2 shared publicationsChao Yu
Center of Interventional Radiology & Vascular Surgery, Department of Radiology, Nurturing Center of Jiangsu Province for State Laboratory of AI Imaging & Interventional Radiology (Southeast University), Basic Medicine Research and Innovation Center of Ministry of Education, Zhongda Hospital, Medical School, Southeast University, Nanjing, People's Republic of China
1 shared publication
Latest Publications
- Open Access
- 27 September 2026
- Published by Wiley in Advanced Science
Glutaminolysis Blockade‐Empowered Bimodal Nanodepot for Spatially Complementary Sono‐Thermal Ablation via PANoptosis and STING Activation Against Large Tumors
Microwave ablation (MWA) for large hepatocellular carcinoma (HCC) is frequently compromised by non‐uniform thermal distribution and immunosuppressive niche formation. To address these challenges, we engineered an injectable bimodal nanodepot (TCPD) via catalytic crosslinking of dopamine‐modified hyaluronic acid by microwave thermal converter cesium‐doped Prussian blue, enabling co‐delivery of glutaminase 1 inhibitor Telaglenastat and sonosensitizer Chlorin e6. Under combined MWA and ultrasound irradiation, TCPD nanodepot disrupts cellular antioxidant defenses and bioenergetic pathways through glutaminolysis‐TCA cycle blockade, metabolically sensitizing large tumors to spatially complementary sono‐thermal ablation and enabling complete treatment coverage. This multimodal intervention induces multiple subcellular stresses, including mitochondrial and endoplasmic reticulum dysfunction, genotoxicity, and NAD + depletion, which converge to facilitate PANoptosome assembly and immunogenic PANoptosis while activating the cGAS‐STING pathway. Subsequent release of damage‐associated molecular patterns and immunoregulatory cytokines promotes dendritic cell maturation, M1 macrophage polarization, and T lymphocyte infiltration, ultimately reprogramming the immunosuppressive microenvironment toward an immune‑activated niche. Integration with anti‐PD‐1 therapy further reinvigorates cytotoxic T lymphocytes and establishes antitumor immune memory to suppress tumor progression and metastasis, offering a multimodal therapeutic strategy for large HCC.
- 27 September 2026
- Published by Wiley in Advanced Science
Open AccessGlutaminolysis Blockade‐Empowered Bimodal Nanodepot for Spatially Complementary Sono‐Thermal Ablation via PANoptosis and STING Activation Against Large Tumors
Microwave ablation (MWA) for large hepatocellular carcinoma (HCC) is frequently compromised by non‐uniform thermal distribution and immunosuppressive niche formation. To address these challenges, we engineered an injectable bimodal nanodepot (TCPD) via catalytic crosslinking of dopamine‐modified hyaluronic acid by microwave thermal converter cesium‐doped Prussian blue, enabling co‐delivery of glutaminase 1 inhibitor Telaglenastat and sonosensitizer Chlorin e6. Under combined MWA and ultrasound irradiation, TCPD nanodepot disrupts cellular antioxidant defenses and bioenergetic pathways through glutaminolysis‐TCA cycle blockade, metabolically sensitizing large tumors to spatially complementary sono‐thermal ablation and enabling complete treatment coverage. This multimodal intervention induces multiple subcellular stresses, including mitochondrial and endoplasmic reticulum dysfunction, genotoxicity, and NAD + depletion, which converge to facilitate PANoptosome assembly and immunogenic PANoptosis while activating the cGAS‐STING pathway. Subsequent release of damage‐associated molecular patterns and immunoregulatory cytokines promotes dendritic cell maturation, M1 macrophage polarization, and T lymphocyte infiltration, ultimately reprogramming the immunosuppressive microenvironment toward an immune‑activated niche. Integration with anti‐PD‐1 therapy further reinvigorates cytotoxic T lymphocytes and establishes antitumor immune memory to suppress tumor progression and metastasis, offering a multimodal therapeutic strategy for large HCC.
- 18 December 2024
- Published by Elsevier in Biomaterials
- Vol. 316, 123018
Pickering emulsion with tumor vascular destruction and microenvironment modulation for transarterial embolization therapy
- 18 December 2024
- Published by Elsevier in Biomaterials
- Vol. 316, 123018
Pickering emulsion with tumor vascular destruction and microenvironment modulation for transarterial embolization therapy
- Open Access
- 1 September 2024
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 19, 9889-9919
Enteral Route Nanomedicine for Cancer Therapy
With the in-depth knowledge of the pathological and physiological characteristics of the intestinal barrier–portal vein/intestinal lymphatic vessels–systemic circulation axis, oral targeted drug delivery is frequently being renewed. With many advantages, such as high safety, convenient administration, and good patient compliance, many researchers have begun to explore targeted drug delivery from intravenous injections to oral administration. Over the past few decades, the fields of materials science and nanomedicine have produced various drug delivery platforms that hold great potential in overcoming the multiple barriers associated with oral drug delivery. However, the oral transport of particles into the systemic circulation is extremely difficult due to immune rejection and biochemical invasion in the intestine, which limits absorption and entry into the bloodstream. The feasibility of the oral delivery of targeted drugs to sites outside the gastrointestinal tract (GIT) is unknown. This article reviews the biological barriers to drug absorption, the in vivo fate and transport mechanisms of drug carriers, the theoretical basis for oral administration, and the impact of carrier structural evolution on oral administration to achieve this goal. Finally, this article reviews the characteristics of different nano-delivery systems that can enhance the bioavailability of oral therapeutics and highlights their applications in the efficient creation of oral anticancer nanomedicines.
- 1 September 2024
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 19, 9889-9919
Open AccessEnteral Route Nanomedicine for Cancer Therapy
With the in-depth knowledge of the pathological and physiological characteristics of the intestinal barrier–portal vein/intestinal lymphatic vessels–systemic circulation axis, oral targeted drug delivery is frequently being renewed. With many advantages, such as high safety, convenient administration, and good patient compliance, many researchers have begun to explore targeted drug delivery from intravenous injections to oral administration. Over the past few decades, the fields of materials science and nanomedicine have produced various drug delivery platforms that hold great potential in overcoming the multiple barriers associated with oral drug delivery. However, the oral transport of particles into the systemic circulation is extremely difficult due to immune rejection and biochemical invasion in the intestine, which limits absorption and entry into the bloodstream. The feasibility of the oral delivery of targeted drugs to sites outside the gastrointestinal tract (GIT) is unknown. This article reviews the biological barriers to drug absorption, the in vivo fate and transport mechanisms of drug carriers, the theoretical basis for oral administration, and the impact of carrier structural evolution on oral administration to achieve this goal. Finally, this article reviews the characteristics of different nano-delivery systems that can enhance the bioavailability of oral therapeutics and highlights their applications in the efficient creation of oral anticancer nanomedicines.
- 26 April 2022
- Published by Elsevier in Acta Biomaterialia
- Vol. 146, 495-505
Biodegradable PTX-PLGA-coated magnesium stent for benign esophageal stricture: An experimental study
- 26 April 2022
- Published by Elsevier in Acta Biomaterialia
- Vol. 146, 495-505
Biodegradable PTX-PLGA-coated magnesium stent for benign esophageal stricture: An experimental study